Scienture Holdings, Inc. (formerly TRxADE Health, Inc.) filed its Form 10-Q with the SEC on November 16, 2026, covering the quarterly period ended September 30, 2026.

Key Highlights

  • Total assets of $87,184,306 as of September 30, 2026, up from $84,178,330 as of December 31, 2025, according to the filing.
  • Cash and cash equivalents declined to $4,747,439 as of September 30, 2026, compared with $6,662,008 as of December 31, 2025.
  • Total liabilities rose to $28,440,722 as of September 30, 2026, from $14,057,946 as of December 31, 2025, with the company disclosing a new note payable totaling $10,826,277 (current and non-current portions combined).
  • Accounts receivable increased to $2,220,101 from $731,328 at year-end 2025, while inventory grew to $998,109 from $213,408.
  • Common shares outstanding were 1,787,953 as of November 13, 2026, up from 1,625,232 as of December 31, 2025.
  • Going concern doubt noted in the filing's forward-looking risk factors, citing "a substantial doubt about our ability to continue as a going concern."
  • Intangible assets of $69,611,525 represented the largest single asset on the balance sheet as of September 30, 2026.

Scienture Holdings Reports Balance Sheet Changes Through September 30, 2026

Scienture Holdings, Inc., formerly operating under the name TRxADE Health, Inc. and listed on NASDAQ:SCNX, filed its quarterly report for the period ended September 30, 2026. The company is incorporated in Delaware, maintains its principal offices at 20 Austin Blvd., Commack, NY 11725, and is classified as a non-accelerated filer and smaller reporting company, according to the filing.

The condensed consolidated balance sheet shows total assets of $87,184,306 as of September 30, 2026. Intangible assets, net, of $69,611,525 accounted for the dominant share of that total, with the company also carrying $5,000,000 in notes receivable and $3,030,085 in restricted cash that did not appear on the December 31, 2025 balance sheet. Interest receivable rose to $531,250 from $250,000 over the same period, according to the filing.

On the liabilities side, the filing discloses that total liabilities more than doubled to $28,440,722 from $14,057,946 at year-end 2025, driven primarily by the appearance of a note payable with a current portion of $1,626,602 and a non-current portion of $9,199,675, as well as an increase in accounts payable from $1,443,266 to $4,142,469. Accrued liabilities also climbed to $1,938,526 from $657,034. The filing's forward-looking disclosures identify "our limited amount of cash" and going concern doubt as among the risk factors facing the company, and caution that "these forward-looking statements are not guarantees of future performance."

What Was Disclosed

Scienture Holdings, Inc. filed a Form 10-Q for the quarterly period ended September 30, 2026, disclosing unaudited condensed consolidated balance sheet data, forward-looking risk factors including going concern language, and updated share counts, with 1,787,953 common shares outstanding as of November 13, 2026.